Tanimilast (CHF-6001) is under development for the treatment of chronic obstructive pulmonary disease, chronic bronchitis and uncontrolled asthma. It is formulated as a dry powder via NEXThaler (dry ...
Asthma is an inflammatory airway disease that is characterized by variable airflow obstruction and bronchial hyper-reactivity (BHR). Typical symptoms include wheezing, breathlessness, chest ...